Page last updated: 2024-10-15

2-[(4-chlorophenyl)methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one

Cross-References

ID SourceID
PubMed CID135412054
CHEMBL ID473326
CHEBI ID93342

Synonyms (24)

Synonym
MLS000062185 ,
smr000070991
2-[(4-chlorobenzyl)thio]-3,5,6,7-tetrahydro-4h-cyclopenta[d]pyrimidin-4-one
OPREA1_513869
OPREA1_558114
SR-01000464438-2
CHEMBL473326 ,
SR-01000627583-2
2-[(4-chlorophenyl)methylsulfanyl]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
AKOS001659025
ml033
SR-01000627583-3
sr-01000627583
HMS2339I08
2-[(4-chlorophenyl)methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
cid_2047223
bdbm40467
2-[(4-chlorobenzyl)thio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
bdbm50031314
sr-01000464438
SR-01000464438-1
CHEBI:93342
Q27165053
CCG-317667

Dosage Studied

ExcerptReference
" Thirty-four compounds from the HTS produced pharmacological dose-response curves."( High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.
Baillargeon, PE; Chase, PS; Fields, GB; Hodder, P; Lauer-Fields, JL; Minond, D; Saldanha, SA; Stawikowska, R, 2009
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency1.77830.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency25.92900.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency4.46680.001815.663839.8107AID894
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency112.20200.050127.073689.1251AID588590
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)40.00000.00020.850210.0000AID641879
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)8.60000.00011.774010.0000AID1169709
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)20.00000.00011.753610.0000AID1169715; AID1169716
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)20.00000.00081.88487.9000AID1169711
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)20.00000.00002.015110.0000AID1169714
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)19.00000.00002.800510.0000AID1169712
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)100.00000.00000.705310.0000AID370889
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)20.00000.00113.418610.0000AID1169710
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)70.00000.00000.927210.0000AID370888; AID641880
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)6.50000.00002.398310.0000AID1169713
Collagenase 3Homo sapiens (human)IC50 (µMol)3.82400.00000.767510.0000AID1169664; AID1169667; AID370629; AID370873; AID370874
Collagenase 3Homo sapiens (human)Ki3.80000.00000.47593.8000AID641812
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Collagenase 3Homo sapiens (human)Kb3.30001.20002.00003.3000AID1169665
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (83)

Processvia Protein(s)Taxonomy
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID641888Inhibition of MMP20 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID641816Inhibition of MMP8 expressed in CHO-K1 cells using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169714Inhibition of CYP2D6 (unknown origin) using dextromethophan substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169668Inhibition of full-length recombinant human MMP-13 assessed as prevention of bovine type-2 collagen degradation at 10 uM after 18 hrs by cartilage explant assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169688Inhibition of recombinant human furin using RRVKRSLD substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169709Inhibition of CYP1A2 (unknown origin) using tacrin substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169686Inhibition of recombinant human cathepsin S using RTLTAK substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370881Inhibition of human recombinant ADAM8 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370895Inhibition of human recombinant ADAMTS1 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370884Inhibition of human recombinant MMP15 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169672Inhibition of recombinant human MMP-9 using GRIGFL substrate up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169715Inhibition of CYP3A4 (unknown origin) using midazolam substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641817Inhibition of recombinant MMP9 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370897Inhibition of human recombinant ACE2 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 200 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370873Inhibition of human recombinant MMP13 by fluorogenic substrate assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169675Inhibition of recombinant human MMP-13 using GRIGFL substrate assessed as inhibition of enzyme activity up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641885Inhibition of MMP12 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID641879Inhibition of MMP1 expressed in Escherichia coli using triple-helical fTHP-15 as substrate after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169682Inhibition of recombinant human caspase 6 using VEHDGG substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169708Half life in rat liver microsomes by LC-MS/MS analysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370886Inhibition of human recombinant MMP24 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641880Inhibition of MMP8 expressed in CHO-K1 cells using triple-helical fTHP-15 as substrate after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169684Inhibition of recombinant human cathepsin K using HHQKLVFFAE substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370629Inhibition of human recombinant MMP13 expressed in Escherichia coli2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.
AID1169711Inhibition of CYP2C8 (unknown origin) using amodiaquine substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370887Inhibition of human recombinant ADAMTS5 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641883Inhibition of MMP3 expressed in Escherichia coli assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID641814Inhibition of MMP1 expressed in Escherichia coli using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370893Inhibition of human recombinant ADAM12 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 200 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169713Inhibition of CYP2C19 (unknown origin) using (S)-mephentoin substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370879Inhibition of human recombinant MMP12 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641818Inhibition of MMP14 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169716Inhibition of CYP3A4 (unknown origin) using testosterone substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370888Inhibition of human recombinant MMP8 by fluorogenic substrate assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169667Inhibition of full-length recombinant human MMP-13 assessed as bovine type-2 collagen hydrolysis after 18 hrs by ELISA2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641881Inhibition of MMP1 expressed in Escherichia coli assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169670Inhibition of recombinant human MMP-2 using GRIGFL substrate up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169671Inhibition of recombinant human MMP-3 using GRIGFL substrate up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370894Inhibition of human recombinant ADAM17 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641813Inhibition of TACE at 40 uM2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370885Inhibition of human recombinant MMP16 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641811Inhibition of human full length recombinant MMP13 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370892Inhibition of human recombinant ADAM10 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370875Inhibition of human recombinant MMP2 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169680Inhibition of recombinant human caspase 3 using DEVDAA substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641884Inhibition of MMP8 expressed in CHO-K1 cells assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370900Inhibition of human recombinant MMP9 at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169689Inhibition of recombinant human thrombin using PRTLT substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169687Inhibition of recombinant human factor 10a using ALPRTMFIQ substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370901Inhibition of human recombinant ADAMTS4 at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169665Non-competitive inhibition of full-length recombinant human MMP-13 assessed as fTHP-15 substrate hydrolysis by Lineweaver-Burke plot analysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370883Inhibition of human recombinant MMP14 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169664Non-competitive inhibition of full-length recombinant human MMP-13 assessed as fTHP-15 substrate hydrolysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169674Inhibition of recombinant human ACE using RPFNYLAK substrate up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370898Inhibition of human recombinant METAP2 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 200 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169683Inhibition of recombinant human caspase 7 using DEVDAA substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169678Inhibition of recombinant human caspase 1 using WEHDGPKR substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID1169681Inhibition of recombinant human caspase 5 using LEHDGP substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370902Inhibition of human recombinant neprilysin at 200 uM by HxBP-Rh probe-based competitive activity based protein profiling assay in presence of 200 uM HxBP-alkyne2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169673Inhibition of recombinant human MMP-12 using GRIGFL substrate up to 20 uM2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370874Inhibition of human recombinant MMP13 by HxBPyne probe-based competitive activity based protein profiling assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169679Inhibition of recombinant human caspase 2 using DEVDAA substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370877Inhibition of human recombinant MMP8 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370889Inhibition of human recombinant MMP9 by fluorogenic substrate assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641882Inhibition of human MMP2 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370878Inhibition of human recombinant MMP10 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169712Inhibition of CYP2C9 (unknown origin) using diclofenac substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370891Inhibition of human recombinant MMP7 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169685Inhibition of recombinant human cathepsin L using GGALRAG substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370880Inhibition of human recombinant PILS-AP at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370872Inhibition of human recombinant L-RAP at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169706Half life in human liver microsomes by LC-MS/MS analysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641812Noncompetitive inhibition of human full length recombinant MMP13 using triple-helical fTHP-15 as substrate by Lineweaver-Burk plot analysis2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169707Half life in mouse liver microsomes by LC-MS/MS analysis2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID641815Inhibition of human MMP2 using triple-helical fTHP-15 as substrate at 40 uM after 4 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID370890Inhibition of human recombinant MMP1 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169677Inhibition of recombinant human cathepsin D using EVNLDAEFRK substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370899Inhibition of human recombinant APP1 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 200 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641886Inhibition of human full length recombinant MMP13 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169690Inhibition of recombinant human uPA using GRTSSVEP substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370876Inhibition of human recombinant MMP3 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID370896Inhibition of human recombinant MMP13 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID1169676Inhibition of recombinant human BACE1 using SEVNLDAEFRKKRR substrate at up to 20 uM after 3 hrs2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID370882Inhibition of human recombinant MMP11 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.
AID641887Inhibition of MMP14 assessed as residual activity using Knight SSP as substrate at 100 uM after 1.5 to 4 hrs by spectrofluorometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
AID1169710Inhibition of CYP2B6 (unknown origin) using bupropion substrate2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's5 (55.56)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]